AVITA Medical (FRA:51KA) ROCE % : -28.06% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AVITA Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was -28.06%.

AVITA Medical ROCE % Historical Data

The historical data trend for AVITA Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical ROCE % Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-144.40

-87.50

-26.78

-27.81

-36.24

AVITA Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-23.10	-43.32	-53.62	-49.44	-28.06

AVITA Medical ROCE % Calculation

AVITA Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-31.336	/	( ( (92.761 - 10.094)	+	(102.374 - 12.103) )	/ 2 )
	=	-31.336	/	( (82.667	+	90.271)	/ 2 )
	=	-31.336	/	86.469
	=	-36.24 %

AVITA Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-21.756	/	( ( (75.91 - 11.09)	+	(102.374 - 12.103) )	/ 2 )
	=	-21.756	/	( ( 64.82	+	90.271 )	/ 2 )
	=	-21.756	/	77.5455
	=	-28.06 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

AVITA Medical (FRA:51KA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AVITA Medical ROCE % Related Terms

Thank you for viewing the detailed overview of AVITA Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical (FRA:51KA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (FRA:51KA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RCEL:USA AVHHL:USA 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.

AVITA Medical (FRA:51KA) Headlines

No Headlines